Are the newer antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review

References

• Wells K B. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. American Journal of Psychiatry 1999; 156: 5–10
   PubMed Web of Science ®Google Scholar
• Healy D. The Antidepressant Era. Harvard University Press, Cambridge 1997
   Google Scholar
• Janicak P G, Davis J M, Preskorn S H, Ayd F J. Principles and practice of psychopharmacotherapy. Management of an acute depressive episode. Williams & Wilkins, Baltimore, MD 1993; 226–246
   Google Scholar
• Agency for Health Care Policy and Research. Treatment of depression newer pharmacotherapies. Summary. Report from University of Texas Health Science Center, San Antonio, TX 1999, Evidence Report No. 7.
   Google Scholar
• Schatzberg A. Antidepressant effectiveness in severe depression and melancholia. Journal of Clinical Psychiatry 1999; 60: 14–21, (Suppl. 4)
   PubMed Web of Science ®Google Scholar
• The Quality Assurance Project. A treatment outline for depressive disorders. Australian and New Zealand Journal of Psychiatry 1983; 17: 129–146
   PubMed Web of Science ®Google Scholar
• Overall J E, Hollister L E, Porkorny A D, Casey J R, Katz G. Drug therapy in depressions. Controlled evaluation of imipramine, isocarboxazid, dextroamphetamine-amobarbital and placebo. Clinical Pharmacology and Therapeutics 1962; 3: 16–22
   PubMed Web of Science ®Google Scholar
• Medical Research Council. Clinical trial of the treatment of depressive illness. British Medical Journal 1965; 1: 831–836
   PubMed Web of Science ®Google Scholar
• Lader M, Herrington R. Biological Treatments in Psychiatry. 2nd ed. Oxford University Press, Oxford 1996
   Google Scholar
• Danish University Antidepressant Group. Citalopram. Clinical effect profile and comparison with Clomipramine: a controlled multicenter study. Psychopharmacology (Berlin) 1986; 90: 131–138
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group. Paroxetine. A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than Clomipramine in a controlled multicenter study. Journal of Affective Disorders 1990; 18: 289–299
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 1993; 28: 105–116
   PubMed Web of Science ®Google Scholar
• Roose S P, Glassman A H, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry 1994; 151: 1735–1739
   PubMed Web of Science ®Google Scholar
• Peselow E D, Sanfilip M P, Difiglia Q, Fieve R R. Melancholic/endogenous depression and response to somatic treatment and placebo. American Journal of Psychiatry 1992; 149: 1324–1334
   PubMed Web of Science ®Google Scholar
• Nelson J C, Mazure C M, Jadow P I. Characteristics of desipramine-refractory depression. Journal of Clinical Psychiatry 1994; 55: 12–19
   PubMed Web of Science ®Google Scholar
• Fava M, Uebelacker L A, Alpert J E, Nierenberg A, Pava J A, Rosenbaum J F. Major depressive sub-types and treatment response. Biological Psychiatry 1997; 42: 568–576
   PubMed Web of Science ®Google Scholar
• Parker G, Hadzi-Pavlovic D. Melancholia. A disorder of movement and mood. Cambridge University Press, New York 1996
   Google Scholar
• American Psychiatric Association. Treatment of Psychiatric Disorders, 3. American Psychiatric Association, Washington 1989
   Google Scholar
• Crismon M L, Trivedie M, Pigott T A, et al. The Texas Medication Algorithm Project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. Journal of Clinical Psychiatry 1999; 60: 142–156
   PubMed Web of Science ®Google Scholar
• Hylan T R, Kotsanos J G, Anderson J S, et al. Comparison of a decision analytic model with results from a naturalistic economic clinical trial: an application to evaluating alternative antidepressants. American Journal of Managed Care 1996; 2: 1211–1223
   Google Scholar
• Rosenbaum J F, Hylan T R. Costs of depressive Disorders. Evidence and practice in psychiatry: depressive disorders, M Maj. World Psychiatric Association, Geneva, (in press)
   Google Scholar
• Parker G, Roy K, Hadzi-Pavlovic D, et al. Sub-typing depression by clinical features: the Australasian data base. Acta Psychiatrica Scandinavica, (in press)
   Google Scholar
• Abrams R. Electroconvulsive therapy. 3rd ed. Oxford University Press, New York 1997
   Google Scholar
• Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy: recommendations for treatment, training and privileging. American Psychiatric Association, Washington, DC 1999
   Google Scholar
• Boyce P, Judd F. The place for the tricyclic antidepressants in the treatment of depression. Australian and New Zealand Journal of Psychiatry 1999; 33: 323–327
   PubMed Web of Science ®Google Scholar
• Beerworth E E, Tiller J WG. Liability in prescribing choice: the example of the antidepressants. Australian and New Zealand Journal of Psychiatry 1998; 32: 560–566
   PubMed Web of Science ®Google Scholar